Verrica Pharmaceuticals Stock (NASDAQ: VRCA)

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Super Micro Computer Inc.

News

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

ARDT

SMCI

VRCA

This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday (CORRECTED)

YUMC

Earnings

Equities

Eurozone

Commodities

Markets

BNOX

VMEO

ZVSA

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Wall Street

S&amp;P 500 Gains 1%; Vimeo Shares Spike Higher

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals Inc

Press Releases

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Management

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

Financing

Verrica Announces Proposed Public Offering

Verrica Announces Pricing of $42.0 Million Public Offering

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verrica Provides Business and Operational Update

Health Care

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Assertio Holdings

CalciMedica

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Grace Therapeutics

Ikena Oncology

Opus Genetics

Iterum Therapeutics

NRX Pharmaceuticals

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

Veru

VYNE Therapeutics

RBC Capital

TD Cowen

Needham

Jefferies

Comments

Verrica Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga